Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 11/20 | 0.44 |
| ▸ | CA1 | P00915 | 11/20 | 0.44 |
| ▸ | CA2 | P00918 | 11/20 | 0.44 |
| ▸ | CA9 | Q16790 | 11/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12871568 | 0.94 | LMNA (0.50) | LMNAKMT2APOLBALDH1A1PAX8 | |
| SCHEMBL12983536 | 0.89 | LMNA (0.50) | LMNAKMT2APOLBALDH1A1PRKCA | |
| SCHEMBL13814376 | 0.88 | LMNA (0.46) | LMNAKMT2APOLBALDH1A1PAX8 | |
| SCHEMBL15417845 | 0.85 | LMNA (0.46) | LMNAKMT2APOLBALDH1A1PRKCA | |
| SCHEMBL12885740 | 0.83 | LMNA (0.46) | LMNAKMT2APOLBALDH1A1CA12 | |
| SCHEMBL13038846 | 0.83 | LMNA (0.46) | LMNAKMT2APOLBALDH1A1CA12 | |
| SCHEMBL12871553 | 0.83 | LMNA (0.46) | LMNAKMT2APOLBALDH1A1CA12 | |
| SCHEMBL13038834 | 0.83 | LMNA (0.46) | LMNAKMT2APOLBALDH1A1CA12 | |
| SCHEMBL19731870 | 0.82 | LMNA (0.48) | LMNAKMT2APOLBALDH1A1PRKCA | |
| SCHEMBL19731895 | 0.81 | LMNA (0.48) | LMNAKMT2APOLBALDH1A1PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464116-B2 | Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140271817-A1 | NOVEL GLYCOCONJUGATES, GLYCOAMINO ACIDS, INTERMEDIATES THERETO, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271817-A1 | NOVEL GLYCOCONJUGATES, GLYCOAMINO ACIDS, INTERMEDIATES THERETO, AND USES THEREOF | SIGLEC7, B3GAT3, FUT6 | LMNA 3771/4885KMT2A 2829/4885POLB 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.